Mostrando 10 resultados de: 18
Filtros aplicados
Publisher
Pharmacogenomics(9)
Drug Metabolism and Drug Interactions(3)
Pharmacogenomics Journal(2)
British Journal of Clinical Pharmacology(1)
Clinical Therapeutics(1)
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., Lares-Asseff I., Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 variation, behaviour and psychopathology: Implications for pharmacogenomics-guided clinical trials
ArticleAbstract: Individual and population differences in polymorphic cytochrome P450 enzyme function have been knownPalabras claves:clinical trials, CYP2D6, endogenous compound metabolism, personality traits, pharmacogenetics, psychopathologyAutores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopus